We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Survey Uncovers Public Feelings Towards Vaccine Equality
News

Survey Uncovers Public Feelings Towards Vaccine Equality

Survey Uncovers Public Feelings Towards Vaccine Equality
News

Survey Uncovers Public Feelings Towards Vaccine Equality

Credit: Nataliya Vaitkevich/ pexels
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Survey Uncovers Public Feelings Towards Vaccine Equality"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Covid-19 pandemic has fundamentally changed the world. It has also revealed many new questions. The fact that a vaccine can be developed, produced and distributed already during a global health crisis is a completely new phenomenon. But what principles should be used to distribute that vaccine? Insufficient production and inadequate distribution capacities around the world have pushed this question to the fore. A research team from the University of Göttingen conducted a representative survey in Germany and America in June 2021 to uncover how the public feels about this. The results were published in the journal Vaccine.


The researchers developed a questionnaire to measure public opinion about global vaccine distribution. They surveyed a total of around 2,000 people, representative of the populations in Germany and the US. For example, distribution experiments with hypothetical volumes of vaccine shipments to be allocated by participants and the “Analytical Hierarchy Process” (AHP) method were used. AHP evaluates several individual decision-making criteria for vaccine distribution against other criteria in a series of pair-wise comparisons. "In particular, we were interested about people’s sincerity regarding such answers and decisions," explains Dr. Ida Monfared, corresponding author for the study, Centre for Modern Indian Studies (CeMIS) at the University of Göttingen. Thus, vaccine distribution decisions were consciously re-evaluated when it was hypothetically a question of one's own vaccination or the vaccination of close family members. Special attention was paid to the question of distribution between countries in the northern and southern hemisphere.


The public in Germany and the US prefer the distribution of Covid-19 vaccines to follow the principle of "medical urgency" (Germany: 49.4 percent, US: 37.4 percent) and the principle of "equal access for all" (Germany: 25.4 percent, US: 32.7 percent). Other possible principles for distribution, such as according to a country's own development and production capacity for vaccines, or according to free market regulation and so according to the purchasing power of the countries, found hardly any support in Germany or the US (less than 15 percent of the share of the vote in each case).


"It was a real surprise to find that there was such willingness to share vaccine, especially in view of the fact that at the time of the survey in mid-2021, there was still no clear evidence on the dangers posed by virus variants in Covid-19. The logistics for a globally coordinated distribution of vaccine should have been developed more clearly and much earlier," says Professor Matthias Klumpp from the Chair of Production and Logistics at Göttingen University.


Reference: Klumpp M, Monfared IG, Vollmer S. Public opinion on global distribution of COVID-19 vaccines: Evidence from two nationally representative surveys in Germany and the United States. Vaccine. 2022. doi: 10.1016/j.vaccine.2022.02.084


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement